Candel Therapeutics, Inc. CADL Operating lease liabilities
Operating lease liabilities at other companies
Other financials
Where this comes from
Reported directly by Candel Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.
The official record: Candel Therapeutics, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Candel Therapeutics, Inc.'s operating lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Candel Therapeutics, Inc.'s operating lease liabilities?
- Candel Therapeutics, Inc. (CADL) reported operating lease liabilities of -$108K in Q1 2026.
- How has Candel Therapeutics, Inc.'s operating lease liabilities changed year-over-year?
- Candel Therapeutics, Inc.'s operating lease liabilities increased by 20.6% year-over-year, from -$136K to -$108K.
- What is the long-term trend for Candel Therapeutics, Inc.'s operating lease liabilities?
- Over 3 years (2022 to 2025), Candel Therapeutics, Inc.'s operating lease liabilities has grown at a 3.1% compound annual growth rate (CAGR), from -$464K to -$509K.